Central Asia: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports in Central Asia

In 2022, overseas shipments of medicaments containing insulin but not antibiotics in measured doses decreased by -7.3% to X kg, falling for the second year in a row after two years of growth. Over the period under review, exports recorded a precipitous decline. The pace of growth was the most pronounced in 2019 when exports increased by 8,700%. Over the period under review, the exports reached the maximum at X tons in 2012; however, from 2013 to 2022, the exports stood at a somewhat lower figure.

In value terms, prophylactic medicaments containing insulin exports expanded remarkably to $X in 2022. Overall, exports showed a sharp decline. The pace of growth was the most pronounced in 2019 when exports increased by 225,935% against the previous year. Over the period under review, the exports attained the peak figure at $X in 2012; however, from 2013 to 2022, the exports failed to regain momentum.

Exports by Country

In 2022, Kazakhstan (X kg) represented the main exporter of medicaments containing insulin but not antibiotics in measured doses in Central Asia, constituting 100% of total export.

Kazakhstan was also the fastest-growing in terms of the medicaments containing insulin but not antibiotics in measured doses exports, with a CAGR of -22.7% from 2012 to 2022. The shares of the largest exporters remained relatively stable throughout the analyzed period.

In value terms, Kazakhstan ($X) also remains the largest prophylactic medicaments containing insulin supplier in Central Asia.

In Kazakhstan, prophylactic medicaments containing insulin exports contracted by an average annual rate of -21.0% over the period from 2012-2022.

Export Prices by Country

The export price in Central Asia stood at $X per ton in 2022, picking up by 18% against the previous year. Overall, the export price posted a moderate expansion. The most prominent rate of growth was recorded in 2019 when the export price increased by 2,469% against the previous year. The level of export peaked in 2022 and is likely to continue growth in the immediate term.

As there is only one major export destination, the average price level is determined by prices for Kazakhstan.

From 2012 to 2022, the rate of growth in terms of prices for Kazakhstan amounted to +2.3% per year.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports in Central Asia

In 2022, overseas purchases of medicaments containing insulin but not antibiotics in measured doses increased by 40% to X tons, rising for the third year in a row after two years of decline. In general, imports showed a buoyant increase. The most prominent rate of growth was recorded in 2017 when imports increased by 56%. The volume of import peaked in 2022 and is likely to see gradual growth in the immediate term.

In value terms, prophylactic medicaments containing insulin imports skyrocketed to $X in 2022. Over the period under review, imports posted a resilient increase. The pace of growth appeared the most rapid in 2020 with an increase of 58%. Over the period under review, imports hit record highs in 2022 and are likely to see gradual growth in years to come.

Imports by Country

In 2022, Kazakhstan (X tons) represented the main importer of medicaments containing insulin but not antibiotics in measured doses, achieving 68% of total imports. Uzbekistan (X tons) held a 19% share (based on physical terms) of total imports, which put it in second place, followed by Kyrgyzstan (5.2%) and Turkmenistan (5%). Mongolia (X tons) held a relatively small share of total imports.

From 2012 to 2022, average annual rates of growth with regard to prophylactic medicaments containing insulin imports into Kazakhstan stood at +10.2%. At the same time, Turkmenistan (+24.8%), Mongolia (+15.2%), Uzbekistan (+8.3%) and Kyrgyzstan (+8.1%) displayed positive paces of growth. Moreover, Turkmenistan emerged as the fastest-growing importer imported in Central Asia, with a CAGR of +24.8% from 2012-2022. Uzbekistan (+19 p.p.) and Turkmenistan (+3.2 p.p.) significantly strengthened its position in terms of the total imports, while Kyrgyzstan and Kazakhstan saw its share reduced by -2.8% and -18.1% from 2012 to 2022, respectively. The shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, Kazakhstan ($X) constitutes the largest market for imported medicaments containing insulin but not antibiotics in measured doses in Central Asia, comprising 82% of total imports. The second position in the ranking was taken by Uzbekistan ($X), with a 10% share of total imports. It was followed by Turkmenistan, with a 2.6% share.

In Kazakhstan, prophylactic medicaments containing insulin imports increased at an average annual rate of +8.3% over the period from 2012-2022. In the other countries, the average annual rates were as follows: Uzbekistan (+11.5% per year) and Turkmenistan (+23.8% per year).

Import Prices by Country

The import price in Central Asia stood at $X per ton in 2022, reducing by -14.5% against the previous year. Overall, the import price saw a pronounced decrease. The pace of growth was the most pronounced in 2020 an increase of 36%. The level of import peaked at $X per ton in 2013; however, from 2014 to 2022, import prices failed to regain momentum.

There were significant differences in the average prices amongst the major importing countries. In 2022, amid the top importers, the country with the highest price was Kazakhstan ($X per ton), while Kyrgyzstan ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Uzbekistan (+2.9%), while the other leaders experienced mixed trends in the import price figures.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :